Inovio Pharmaceuticals, Inc. (INO)

6.94
0.20 2.97
NASDAQ
Prev Close 6.74
Open 6.73
Day Low/High 6.66 / 6.95
52 Wk Low/High 5.81 / 19.00
Volume 2.07M
Exchange NASDAQ
Shares Outstanding 210.36B
Market Cap 1.48B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

What's Up at the Fed? Supply & Demand, 12 Trading Notes, Microsoft Conference

What's Up at the Fed? Supply & Demand, 12 Trading Notes, Microsoft Conference

Should we care about Australia's central bank taking overtly aggressive action to reign in the long end of their yield curve? Yes, we should.

A Market No-Doubter, Vaccine Milestone, GDP Green Shoots, Inovio, Amazon, Google

A Market No-Doubter, Vaccine Milestone, GDP Green Shoots, Inovio, Amazon, Google

The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.

The Meaning of Biden, Overbought Markets? Fun With Charts

The Meaning of Biden, Overbought Markets? Fun With Charts

Can corporate America grow sales for the fourth quarter? Then answer a question with a question.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Novavax Could Surprise on the Upside - No Bearish Divergences Yet

Novavax Could Surprise on the Upside - No Bearish Divergences Yet

Let's review the charts and indicators.

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.

Inovio Pharmaceuticals Is Breaking Out on the Upside: Here's Our Strategy

Inovio Pharmaceuticals Is Breaking Out on the Upside: Here's Our Strategy

The price action is very bullish right now so a fresh look is warranted.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

The Fed Has Our Backs, Trading Thoughts, 'Facebook Shops'

The Fed Has Our Backs, Trading Thoughts, 'Facebook Shops'

As State economies begin the slow process of reopening, the Fed is there to support market function. Facebook's latest e-commerce foray has investors cheering.

Jim Cramer: It's Still Better to Be Safe Than Sorry

Jim Cramer: It's Still Better to Be Safe Than Sorry

Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.

Sell Signals, 'Operation Warp Speed,' Trading Notes

Sell Signals, 'Operation Warp Speed,' Trading Notes

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.

Inovio Pharmaceuticals Stands Ready to Reach New Heights

Inovio Pharmaceuticals Stands Ready to Reach New Heights

Current owners of the small biotech company's shares should continue to hold them based on its charts but should put in a stop, too.

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.

Speculative Inovio Pharmaceuticals Could Be a Home Run for Some Investors

Speculative Inovio Pharmaceuticals Could Be a Home Run for Some Investors

This biotech is one of two companies in human trials for a vaccine for Covid-19.

Jim Cramer: 10 Stocks That Millennials Should Own

Jim Cramer: 10 Stocks That Millennials Should Own

A look at some names that Robinhood brokerage CEO Tenev tells us young people are buying.

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.

5 Leading Biotechs in Search of a Coronavirus Vaccine

5 Leading Biotechs in Search of a Coronavirus Vaccine

The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.

Don't Do the Coronavirus Chase

Don't Do the Coronavirus Chase

There are small vaccine and testing companies that see their shares spike when a new virus hits, but whether those gains will last is questionable.

Roller Coaster Markets, Time for Emergency Measures, 3 Stock Groups to Focus On

Roller Coaster Markets, Time for Emergency Measures, 3 Stock Groups to Focus On

I'll stick to the three-pronged approach... the Rebound group, the Virus group, and the Revenue group.

4 Stocks to Buy to Profit From This Panic

4 Stocks to Buy to Profit From This Panic

These sort of panics can be turn out to be lucrative opportunities for investors.

Inovio Rated New Buy at Roth Capital

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

Identifying this week's bullish and bearish reversal patterns.

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.